Cargando…

Biochemical recurrence-free survival and pathological outcomes after radical prostatectomy for high-risk prostate cancer

BACKGROUND: We propose to improve the prognostic assessment after radical prostatectomy (RP) by dividing high-risk prostate cancer (hrPCa) (according to the d’Amico classification) into subgroups combining 1, 2 or 3 criteria of aggressiveness (cT2c-T3a, PSA >20 ng/ml, Gleason score (GS) > 7)....

Descripción completa

Detalles Bibliográficos
Autores principales: Beauval, Jean-Baptiste, Roumiguié, Mathieu, Filleron, Thomas, Benoit, Thibaut, de la Taille, Alexandre, Malavaud, Bernard, Salomon, Laurent, Soulié, Michel, Ploussard, Guillaume
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4897874/
https://www.ncbi.nlm.nih.gov/pubmed/27267988
http://dx.doi.org/10.1186/s12894-016-0146-6
_version_ 1782436252517138432
author Beauval, Jean-Baptiste
Roumiguié, Mathieu
Filleron, Thomas
Benoit, Thibaut
de la Taille, Alexandre
Malavaud, Bernard
Salomon, Laurent
Soulié, Michel
Ploussard, Guillaume
author_facet Beauval, Jean-Baptiste
Roumiguié, Mathieu
Filleron, Thomas
Benoit, Thibaut
de la Taille, Alexandre
Malavaud, Bernard
Salomon, Laurent
Soulié, Michel
Ploussard, Guillaume
author_sort Beauval, Jean-Baptiste
collection PubMed
description BACKGROUND: We propose to improve the prognostic assessment after radical prostatectomy (RP) by dividing high-risk prostate cancer (hrPCa) (according to the d’Amico classification) into subgroups combining 1, 2 or 3 criteria of aggressiveness (cT2c-T3a, PSA >20 ng/ml, Gleason score (GS) > 7). METHODS: Data from 4795 hrPCa patients who underwent RP in two French university hospitals from 1991 to 2013 were analyzed. Subgroups were formed to determine whether an increasing number (1, 2 or 3) of criteria of tumor aggressiveness was associated with poorer oncological results and early biochemical recurrence (BCR) (PSA > 0.2 ng/ml). These results were compared using Fisher’s exact test and BCR was compared according to the Kaplan-Meier method. RESULTS: Eight hundred fifteen patients were treated by RP for hrPCa (8 %). Four hundred eleven patients (79.5 %) presented 1 RF (Risk Factor), 93 (18.0 %) 2 RF and 13 (2.5 %) 3 RF. Lymph node invasion and positive margin rates were 12.4 and 44.1 %, respectively. The prognostic sub-stratification based on these 3 factors was significantly predictive for adverse pathologic features and for oncologic outcomes. BCR free survival was respectively 56.4, 27.06 and 18.46 % for 1RF, 2RF and 3RF (p < 0.0001). However, no predominant negative criterion was found. CONCLUSION: Oncologic results after RP are heterogenous within the hrPCa risk group. Sub-stratification based on three well-defined criteria leads to a better identification of the most aggressive cancers. On the other hand, RP provides both effective cancer control and satisfactory survival rates in patients with only one risk factor. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12894-016-0146-6) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4897874
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-48978742016-06-09 Biochemical recurrence-free survival and pathological outcomes after radical prostatectomy for high-risk prostate cancer Beauval, Jean-Baptiste Roumiguié, Mathieu Filleron, Thomas Benoit, Thibaut de la Taille, Alexandre Malavaud, Bernard Salomon, Laurent Soulié, Michel Ploussard, Guillaume BMC Urol Research Article BACKGROUND: We propose to improve the prognostic assessment after radical prostatectomy (RP) by dividing high-risk prostate cancer (hrPCa) (according to the d’Amico classification) into subgroups combining 1, 2 or 3 criteria of aggressiveness (cT2c-T3a, PSA >20 ng/ml, Gleason score (GS) > 7). METHODS: Data from 4795 hrPCa patients who underwent RP in two French university hospitals from 1991 to 2013 were analyzed. Subgroups were formed to determine whether an increasing number (1, 2 or 3) of criteria of tumor aggressiveness was associated with poorer oncological results and early biochemical recurrence (BCR) (PSA > 0.2 ng/ml). These results were compared using Fisher’s exact test and BCR was compared according to the Kaplan-Meier method. RESULTS: Eight hundred fifteen patients were treated by RP for hrPCa (8 %). Four hundred eleven patients (79.5 %) presented 1 RF (Risk Factor), 93 (18.0 %) 2 RF and 13 (2.5 %) 3 RF. Lymph node invasion and positive margin rates were 12.4 and 44.1 %, respectively. The prognostic sub-stratification based on these 3 factors was significantly predictive for adverse pathologic features and for oncologic outcomes. BCR free survival was respectively 56.4, 27.06 and 18.46 % for 1RF, 2RF and 3RF (p < 0.0001). However, no predominant negative criterion was found. CONCLUSION: Oncologic results after RP are heterogenous within the hrPCa risk group. Sub-stratification based on three well-defined criteria leads to a better identification of the most aggressive cancers. On the other hand, RP provides both effective cancer control and satisfactory survival rates in patients with only one risk factor. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12894-016-0146-6) contains supplementary material, which is available to authorized users. BioMed Central 2016-06-08 /pmc/articles/PMC4897874/ /pubmed/27267988 http://dx.doi.org/10.1186/s12894-016-0146-6 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Beauval, Jean-Baptiste
Roumiguié, Mathieu
Filleron, Thomas
Benoit, Thibaut
de la Taille, Alexandre
Malavaud, Bernard
Salomon, Laurent
Soulié, Michel
Ploussard, Guillaume
Biochemical recurrence-free survival and pathological outcomes after radical prostatectomy for high-risk prostate cancer
title Biochemical recurrence-free survival and pathological outcomes after radical prostatectomy for high-risk prostate cancer
title_full Biochemical recurrence-free survival and pathological outcomes after radical prostatectomy for high-risk prostate cancer
title_fullStr Biochemical recurrence-free survival and pathological outcomes after radical prostatectomy for high-risk prostate cancer
title_full_unstemmed Biochemical recurrence-free survival and pathological outcomes after radical prostatectomy for high-risk prostate cancer
title_short Biochemical recurrence-free survival and pathological outcomes after radical prostatectomy for high-risk prostate cancer
title_sort biochemical recurrence-free survival and pathological outcomes after radical prostatectomy for high-risk prostate cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4897874/
https://www.ncbi.nlm.nih.gov/pubmed/27267988
http://dx.doi.org/10.1186/s12894-016-0146-6
work_keys_str_mv AT beauvaljeanbaptiste biochemicalrecurrencefreesurvivalandpathologicaloutcomesafterradicalprostatectomyforhighriskprostatecancer
AT roumiguiemathieu biochemicalrecurrencefreesurvivalandpathologicaloutcomesafterradicalprostatectomyforhighriskprostatecancer
AT filleronthomas biochemicalrecurrencefreesurvivalandpathologicaloutcomesafterradicalprostatectomyforhighriskprostatecancer
AT benoitthibaut biochemicalrecurrencefreesurvivalandpathologicaloutcomesafterradicalprostatectomyforhighriskprostatecancer
AT delataillealexandre biochemicalrecurrencefreesurvivalandpathologicaloutcomesafterradicalprostatectomyforhighriskprostatecancer
AT malavaudbernard biochemicalrecurrencefreesurvivalandpathologicaloutcomesafterradicalprostatectomyforhighriskprostatecancer
AT salomonlaurent biochemicalrecurrencefreesurvivalandpathologicaloutcomesafterradicalprostatectomyforhighriskprostatecancer
AT souliemichel biochemicalrecurrencefreesurvivalandpathologicaloutcomesafterradicalprostatectomyforhighriskprostatecancer
AT ploussardguillaume biochemicalrecurrencefreesurvivalandpathologicaloutcomesafterradicalprostatectomyforhighriskprostatecancer